Dabrafenib-Trametinib Combo Approved for Range of Solid Tumors Dabrafenib-Trametinib Combo Approved for Range of Solid Tumors

The drug combination, which received accelerated approval from the FDA for patients aged 6 years and older, is the only BRAF/MEK inhibitor okayed for use in pediatric patients.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news